Sign Up to like & get
recommendations!
2
Published in 2023 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s403461
Abstract: Abstract Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has shown promising results in preclinical and clinical studies,…
read more here.
Keywords:
kras g12c;
enigma code;
trial;
codebreak 200 ... See more keywords